ClinicalTrials.gg

Chickenpox clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 180 studies for Chickenpox across more than 10 countries. 28 are recruiting or about to start. 94 of them are mainly about Chickenpox (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-28.

Status

Completed
114
Recruiting
16
Status unknown
14
Active, not recruiting
12
Not yet recruiting
8
Withdrawn
6

Phase

Phase 3
68
Phase 2
36
Phase 4
32
Phase 1
18

Where

United States
44
China
31
Germany
13
Canada
8
Italy
7
Poland
7

Who develops what

Add Chickenpox to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 12 programs from 8 companies, 7 with this as their studies’ main aim; 8 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Sinovac Biotech, GlaxoSmithKline and SK Chemicals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
shingrixRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07481604 · Aribio Lab Co., Ltd. · Phase 2 · live · comparator · “Shingrix” · registered Mar 2026
  • NCT07205796 · Shenzhen Shenxin Biotechnology Co., Ltd · Phase 2 · live · comparator · “Shingrix” · registered Sep 2025
  • NCT05703607 · Pfizer · Phase 2 · comparator · “Shingrix” · registered Jan 2023
  • NCT05304351 · Eli Lilly and Company · Phase 2 · live · comparator · “Shingrix” · registered Dec 2021
GlaxoSmithKline88% of its industry studies44 studies
Chickenpox VaccineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07054099 · GC Biopharma Corp. · Phase 3 · live · comparator · “VARIVAX™” · registered Jul 2025
  • NCT06987942 · Sinovac Biotech Co., Ltd · Phase 4 · comparator · “Varicella vaccine” · registered May 2025
  • NCT06891872 · Sinovac Biotech Co., Ltd · Phase 4 · live · comparator · “Varicella Vaccine” · registered Mar 2025
  • NCT06314724 · Sinovac Biotech Co., Ltd · Phase 3 · comparator · “Varivax” · registered Mar 2024
  • NCT05422508 · GC Biopharma Corp. · Phase 2 · live · comparator · “VARIVAX” · registered May 2022
Merck & Co., Inc43% of its industry studies25 studies

5 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
NBP608☆ Track1 live phase-3 study: NCT07415252SK Chemicals Co., Ltd.
SKYVaricella®☆ Track1 live phase-3 study: NCT07415252SK Chemicals Co., Ltd.
MG1111☆ Track1 live phase-3 study: NCT07054099GC Biopharma Corp.
ABO1108☆ Track1 live phase-3 study: NCT07817108Suzhou Abogen Biosciences Co., Ltd.
Chickenpox VaccinePhase 4 trial recorded☆ Track1 live phase-3 study: NCT07473427Sinovac Biotech Co., Ltd

The 5 in phase 3 with the nearest primary completion, of 12 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jan 2027 est.CVI-VZV-001 · Aribio Lab Co., Ltd. · Phase 2 registry mapping onlyvs shingrixNCT07481604 Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above — primary endpoint: Geometric Mean Fold Rise (GMFR) of Anti-VZV gE Antibody · 135 enrolled
  • 13 Feb 2027 est.NBP608, SKYVaricella® · SK Chemicals Co., Ltd. · Phase 3 main aimNCT07415252 SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years — primary endpoint: Seroconversion rate of varicella-zoster virus(VZV) · 780 enrolled
  • Aug 2027 est.MG1111 · GC Biopharma Corp. · Phase 3 main aim+ MG1111 vs Chickenpox VaccineNCT07054099 A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years — primary endpoint: Proportion of participants who achieved seroconversion at 42 days after second vaccination · 474 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Chickenpox studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

12studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger. 12 (75%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 13 (81%) take healthy volunteers.

Recruiting studies that take each age, of 16
AgeWomenMen
106 (38%)6 (38%)
184 (25%)4 (25%)
303 (19%)3 (19%)
405 (31%)5 (31%)
505 (31%)5 (31%)
654 (25%)4 (25%)
754 (25%)4 (25%)
853 (19%)3 (19%)

Across all 180 studies, recruiting or not: 71% stop at 75 or younger and 67% at 65; 71% take children; 1% are for women only and 0% for men only; 77% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Chickenpox studies take

Of 39 phase 3 interventional studies under Chickenpox, half reached primary completion within 13 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 217 mo7–38 · 17 studies——
Phase 313 mo9–24 · 39 studies12 mo8–15 · 35 studies—
Phase 44 mo2–22 · 14 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 180. Browse all 180 → or search them.